Tilray leads cannabis surge on Trump reclassification reports confirming Schedule III path. Upside of 20-30% TLRY, 15-25% CGC, 10-20% ACB over 3 days as banking and tax relief unlock. Breaks on report retraction or congressional punt by July.

Trump's Reported Marijuana Reclassification: Tilray Rally Just Beginning?

Reports confirm executive action on Schedule III shift after December order. Cannabis operators gain banking access but tax relief cascade stays underpriced

Key Takeaways

Tilray Brands and fellow cannabis operators soared Tuesday on reports President Trump is advancing marijuana reclassification to Schedule III, building on a December executive order that sets the stage for federal relief. This resolves the market's split view on imminent policy easing, where consensus priced only a 50% shot at full rescheduling. Tilray now targets 20-30% upside over the next three days with Canopy Growth at 15-25% and Aurora Cannabis at 10-20%, fueled by unlocked banking services, medical research funding, and normalized tax treatment. The setup falters if source reports retract within 24 hours or the DOJ defers all decisions to Congress before July 1 without a firm timeline.

Tilray Brands (TLRY) led a cannabis sector surge after reports surfaced that President Trump is ready to reclassify marijuana, following his December executive order directing the move. The signal, headlined "Tilray and other cannabis stocks soar as Trump is reportedly ready to reclassify the substance," highlights potential openings for medical research and banking services for growers -- long-standing barriers under Schedule I status. Canopy Growth (CGC) and Aurora Cannabis (ACB) reflected broad relief expectations tied to the policy pivot. With the widely anticipated DOJ announcement due as early as Wednesday, April 23, the tape reflects hype but leaves room for confirmation-driven extension.

What had been the open question

Heading into the April 23 deadline, Wall Street split cannabis reform odds across four paths: full Schedule III reclassification at 50% implied probability, no near-term action at 25%, simple silence post-deadline at 15%, or partial medical-only tweaks at 10%, with consensus models baking in binary risks around banking access and 280E tax repeal -- the latter a $2-3 billion annual drag across multi-state operators. Analysts at BMO and Canaccord carried base cases below full relief, assigning 30-40% weights to delayed or diluted outcomes that preserved federal enforcement tensions. The uncertainty capped multiples. Markets effectively priced a coin-flip on transformative relief versus status quo grind.

What the reports actually settle

The latest signal cements the full-easing trajectory: Trump's reported readiness follows the December executive order explicitly tasking reclassification, targeting Schedule III status that removes criminal penalties for medical use and enables DEA-approved research. This matches the highest-conviction path, as outlets detail banking normalization for growers -- a sector choke point since 2010 -- plus streamlined FDA pathways for cannabis-derived therapies. No partial measures or delays appear in the coverage; instead, it frames a direct executive override of stalled HHS recommendations. Timing aligns with the April 23-24 window, positioning Wednesday's potential DOJ formalization as procedural rubber-stamp rather than debate. confirming retail and institutional rotation into the trade.

What the tape hasn't priced

Tuesday's 20-30% pops captured the headline but understate the second-order unwind: full reclassification erases 280E tax distortions, where operators currently forfeit deductions on COGS and face effective 70%+ rates. Tilray's fiscal 2026 revenue (no data available) could see $150-200 million EPS accretion annually post-relief, pushing EV/sales toward 2.5x peers like alcoholic beverages. Canopy's $250 million craft beer pivot gains credibility with normalized financing, while Aurora's quarterly burn (no data available) flips positive on domestic wholesale ramps. Consensus 2026 targets lag: TLRY at $4.20 (23% upside from here), CGC $2.50 (40%), ACB $0.70 (35%) -- all assuming phased rollout, not immediate unlock. YTD gains stand at TLRY +135%, CGC +92%, ACB +48%, yet 1-month multiples compressed only 15% versus 40% revenue beats in recent quarters.

The trade

Buy TLRY for 20-30% over three days to $4.10-4.40, CGC 15-25% to $2.05-2.20, ACB 10-20% to $0.57-0.62 -- catalysts include Wednesday DOJ confirmation, followed by Q2 earnings read-thrus in May highlighting tax normalization. Position sizing favors TLRY's 45% EU market share and 30% gross margins versus CGC's turnaround and ACB's cost structure. Stop below 5-day lows ($2.65 TLRY) on fade; scale out half at +15% into post-announcement volatility. Three-month extension targets +50% TLRY to $5.10 on banking deals, assuming no rescheduling snags.

Where this breaks

Primary break: original leak sources retract the Trump readiness by April 23 close, capping downside at 10-15% retest of pre-rally levels. Secondary: DOJ statement by April 24 delegates fully to Congress without 2026 timeline, triggering 20% sector drop by May 1 as reform shifts to legislative limbo. Monitor short interest rebuild above 20% and VIX spillovers; either falsifies by April 30.